Immunomedics (IMMU) Income Statement

Click line-items for a historical chart and %

Product sales	597.51K
Research and development	129.19K
Total revenues	741.81K
Costs of goods sold	255.11K
Research and development	14.53M
Sales and marketing	215.86K
General and administrative	691.58K
Total costs and expenses	15.69M
Operating loss	-14.95M
Interest and other income	85.21K
Foreign currency transaction gain	2.46K
Loss before income tax expense
Income tax (expense)	0
Net (loss)	-16.23M
Less net (loss) attributable to noncontrolling interest	-31.05K
Net (loss) attributable to Immunomedics, Inc. stockholders	-16.2M
(Loss) per common share attributable to Immunomedics, Inc. stockholders, (basic and diluted)	-0.17
Weighted average shares used to calculate loss per common share, (basic and diluted)
Net (loss)
Foreign currency translation adjustments
Unrealized gain on securities available for sale - net	-32.61K
Other comprehensive (loss) income
Comprehensive (loss)	-16.19M

Entities mentioned with IMMU

View All Entities